Actuate Therapeutics Files 8-K

TL;DR

Actuate Therapeutics filed an 8-K on 12/17/24 for Reg FD and financials.

AI Summary

Actuate Therapeutics, Inc. filed an 8-K on December 17, 2024, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as Apotheca Therapeutics, Inc. until September 11, 2015, is incorporated in Delaware and headquartered in Fort Worth, Texas.

Why It Matters

This filing indicates routine corporate reporting, including financial statements and disclosures, which are important for investors to stay informed about the company's status.

Risk Assessment

Risk Level: low — This is a standard 8-K filing for corporate disclosures and financial statements, not indicating any immediate material events or risks.

Key Players & Entities

• Actuate Therapeutics, Inc. (company) — Registrant
• Apotheca Therapeutics, Inc. (company) — Former company name
• December 17, 2024 (date) — Date of report
• September 11, 2015 (date) — Date of name change
• Fort Worth, Texas (location) — Principal Executive Offices

FAQ

Key Financial Figures

• $0.000001 — ch registered Common Stock, par value $0.000001 per share ACTU The Nasdaq Stock Mar

Filing Documents

• actuate_8k.htm (8-K) — 36KB
• actuate_ex9901.htm (EX-99.1) — 20KB
• image_001.jpg (GRAPHIC) — 3KB
• 0001683168-24-008794.txt ( ) — 243KB
• actu-20241217.xsd (EX-101.SCH) — 3KB
• actu-20241217_lab.xml (EX-101.LAB) — 33KB
• actu-20241217_pre.xml (EX-101.PRE) — 24KB
• actuate_8k_htm.xml (XML) — 4KB

01. Regulation FD

Item 7.01. Regulation FD. On December 17, 2024, Actuate Therapeutics, Inc. (the "Company") issued a press release announcing positive interim data from its ongoing and fully enrolled randomized Phase 2 trial of elraglusib in combination with gemcitabine/nab-paclitaxel ("GnP") in first line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC) (Actuate-1801 Part 3B). A copy of the press release is furnished herewith as Exhibit 99.1 to this Current Report and is incorporated herein by reference. The Company also updated the investor presentation made available on its website, www.actuatetherapeutics.com, under "Investors" to include the interim data. The information in this Item 7.01, including Exhibit 99.1 and the information on the Company's website, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 , as amended (the " Exchange Act "), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filings under the Securities Act of 1933 , as amended, or the Exchange Act , regardless of any general incorporation language in such filings, unless expressly incorporated by specific reference in such filing. Cautionary Note Regarding Forward Looking Statements This Current Report on Form 8-K contains forward-looking "continue," "could," "estimate," "expect," "intend," "may," "might," "ongoing," "plan," "potential," "predict," "project," "should," "target," "will," "would," or the negative of these terms or other comparable terminology are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. All statements, other than statements related to present facts or current conditions or of historical facts, contained in this Form 8-K are forward-looking

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release of Actuate Therapeutics, Inc. dated December 17, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 3

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Actuate Therapeutics, Inc. Date: December 17, 2024 By: /s/ Daniel M. Schmitt Name: Daniel M. Schmitt Title: President and Chief Executive Officer 4

View Full Filing

View this 8-K filing on SEC EDGAR